Original Research C hronic cough and sputum production are common, but symptoms vary in patients with COPD. 1 They result from goblet cell hyperplasia in both large and small airways, 2-4 and the subsequent mucus hypersecretion worsens airfl ow obstruction and predisposes to bacterial colonization. 5 Mucus overproduction may develop as a consequence of cigarette smoke exposure, 6,7 acute and chronic viral infection, 8 or infl ammatory cell activation of mucin gene transcription 9 and is compounded by diffi culty in clearing secretions because of poor ciliary function, distal airway occlusion, and ineffective cough. 2, 9, 10 Chronic mucus hypersecretion has been shown in some large epidemiologic studies to be associated with an accelerated lung function decline, increased risk for respiratory infection, 11,12 and higher mortality. [13] [14] [15] Several studies have demonstrated an increased risk of COPD exacerbation. [16] [17] [18] [19] Goblet cell hyperplasia also has prognostic value as it has been associated with an increased risk of mortality and a lack of improvement in lung function after lung reduction surgery. 20, 21 Despite these clinical and pathologic correlates of chronic bronchitis (CB) to various clinical outcomes, the current literature is limited regarding Background: Chronic bronchitis (CB) in patients with COPD is associated with an accelerated lung function decline and an increased risk of respiratory infections. Despite its clinical significance, the chronic bronchitic phenotype in COPD remains poorly defi ned. Methods: We analyzed data from subjects enrolled in the Genetic Epidemiology of COPD (COPDGene) Study. A total of 1,061 subjects with GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage II to IV were divided into two groups: CB (CB 1 ) if subjects noted chronic cough and phlegm production for Ն 3 mo/y for 2 consecutive years, and no CB (CB 2 ) if they did not. Results: There were 290 and 771 subjects in the CB 1 and CB 2 groups, respectively. Despite similar lung function, the CB 1 group was younger (62.8 Ϯ 8.4 vs 64.6 Ϯ 8.4 years, P 5 .002), smoked more (57 Ϯ 30 vs 52 Ϯ 25 pack-years, P 5 .006), and had more current smokers (48% vs 27%, P , .0001). A greater percentage of the CB 1 group reported nasal and ocular symptoms, wheezing, and nocturnal awakenings secondary to cough and dyspnea. History of exacerbations was higher in the CB 1 group (1.21 Ϯ 1.62 vs 0.63 Ϯ 1.12 per patient, P , .027), and more patients in the CB 1 group reported a history of severe exacerbations (26.6% vs 20.0%, P 5 .024). There was no difference in percent emphysema or percent gas trapping, but the CB 1 group had a higher mean percent segmental airway wall area (63.2% Ϯ 2.9% vs 62.6% Ϯ 3.1%, P 5 .013). Conclusions: CB in patients with COPD is associated with worse respiratory symptoms and higher risk of exacerbations. This group may need more directed therapy targeting chronic mucus production and smoking cessation not only to improve symptoms but also to reduce risk, improve quality of life, and improve outcomes.
assessed based on subject self-report. Subjects were asked whether they experienced COPD exacerbations in the past year and to quantify the number of episodes. They also were asked whether they had been to the ED or hospitalized for an exacerbation in the past year. These answers were used to determine exacerbation history and history of severe exacerbations, respectively.
Each subject underwent prebronchodilater and postbronchodilator spirometry using an EasyOne spirometer (Welch-Allyn Switzerland GmbH; Vaud, Switzerland ). Predicted values were obtained using National Health and Nutrition Examination Survey III data. 24 Six-min walk distance was measured in the standard fashion. 25 
CT Imaging
Volumetric CT scan acquisitions were obtained at full inspiration (200 mA) and at the end of normal expiration (50 mA). Thinslice collimation with slice thickness and intervals of , 1 mm was used to enhance spatial resolution. Quantitative image analysis to calculate lung volumes, percent emphysema, and percent gas trapping was performed using VIDA (VIDA Diagnostics, Inc; Coralville, Iowa) and 3DSlicer (available at http://www.slicer.org) software. 26 Percent emphysema was defi ned as the total percentage of both lungs with attenuation values , 2 950 Hounsfi eld units on inspiratory images, and percent gas trapping was defi ned as the total percentage of both lungs with attenuation values , 2 856 Hounsfi eld units on expiratory images. These percentages were adjusted for type of CT scanner. Total lung capacity and functional residual capacity were calculated based on inspiratory and expiratory CT images , respectively. Airway disease was quantifi ed in a subset of each group as wall area percent (WA%) [(wall area/total bronchial area) 3 100)] and airway wall thickness (AWT). 27 The mean WA% and AWT were calculated as the average of the values for six segmental bronchi in each subject. Using 3DSlicer, we also expressed AWT as the square root of the wall area of a theoretical 10-mm diameter airway as previously described. 28 
Statistical Analysis
Analysis was performed using JMP, version 8.0.1 (SAS Inc; Cary, North Carolina). Values are expressed as mean Ϯ SD, unless stated otherwise. Categorical variables (eg, sex, race, presence of ocular or nasal symptoms) were compared between groups using x 2 test. Continuous variables (eg, age, smoking history, exacerbation history) were evaluated using one-way analysis of variance or two-tailed unpaired t test. Wilcoxon rank sum test was used for nonnormally distributed data. P , .05 was considered statistically signifi cant. Multiple logistic regressions were performed to assess the independent effects of CB, sex, age, current smoking, and total pack-year history of smoking on symptoms.
Results
Participant demographics and medications are summarized in Table 1 . Of the 1,061 subjects with COPD analyzed, CB was reported in 27.3% (CB 1 group, n 5 290; CB 2 group, n 5 771). The percentage of subjects with CB in each GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage was similar (GOLD stage II, 27.3%; GOLD stage III, 28.7%; GOLD stage IV, 25.0%; P 5 .650). In the entire cohort, the CB 1 group was younger (62.8 Ϯ 8.4 vs 64.6 Ϯ 8.4 years, P 5 .002) and had a greater the clinical and radiographic characteristics of CB in patients with COPD.
We analyzed 1,061 patients with moderate to severe COPD in the fi rst 2,500 subjects enrolled in the Genetic Epidemiology of COPD (COPDGene) Study. We specifi cally sought to carefully characterize those with CB symptoms and compare them to those without these symptoms. We hypothesized that chronic cough and sputum production in patients with COPD are associated with a greater exacerbation frequency, heightened respiratory symptoms, and worse healthrelated quality of life compared with those without CB symptoms.
Materials and Methods

Patient Selection
The COPDGene Study is a multicenter observational study to analyze genetic susceptibility for the development of COPD. This study met all criteria for institutional review board approval (Temple IRB #11369). Inclusion and exclusion criteria and protocol have been described previously. 22 Briefl y, enrollees are blacks or non-Hispanic whites aged 45 to 80 years with at least a 10-packyear smoking history. Exclusion criteria include pregnancy, history of other lung disease except asthma, prior lobectomy or lung volume reduction, active cancer undergoing treatment, or known or suspected lung cancer.
Subjects were asked whether they had cough, and if they responded yes, they were asked whether they coughed on most days for Ն 3 consecutive mo/y and for how many years. Similar questions were asked regarding phlegm production. Subjects were placed in the CB 1 group if they had chronic cough and phlegm production for Ն 3 mo/y for at least 2 consecutive years or in the CB 2 (no CB) group if these criteria were not satisfi ed.
Clinical Characterization
Dyspnea and health-related quality of life were assessed using the Modifi ed Medical Research Council (MMRC) scale and St. George Respiratory Questionnaire (SGRQ). Upper-and lowerrespiratory tract symptoms were collected using a modifi ed form of the American Thoracic Society Diffuse Lung Disease Respiratory Epidemiology questionnaire. 23 Comorbidities also are listed in Table 1 . Compared with the CB 2 group, a greater number of subjects in the CB 1 group reported a history of angina (9.0% vs 4.5%, P 5 .011), diabetes (16.2% vs 10.3%, P 5 .010), gastroesophageal refl ux (34.6% vs 27.6%, P 5 .029), compression fractures (9.7% vs 5.6%, P 5 .027), osteoarthritis (25.9% vs 18.3%, P 5 .008), and sleep apnea (22.4% vs 14.4%, P 5 .002). There were no differences in asthma, congestive heart failure, coronary artery disease, myocardial infarction, hypertension, hypercholesterolemia, stroke, and osteoporosis. When the incidence of angina was controlled for other cardiac risk factors (hypertension, pack-year smoking history, hypercholesterolemia, and diabetes), the presence of CB was still associated with an increased incidence of angina (OR, 1.92; P 5 .02). Table 2 summarizes symptoms, quality of life, and exacerbation history. The subjects in the CB 1 group were more symptomatic than those in the CB 2 group. MMRC, SGRQ, and BODE (BMI, airfl ow obstruction, dyspnea, exercise capacity) index scores were greater in the CB 1 group (MMRC, 2.55 Ϯ 1.31 vs 2.11 Ϯ 1.41, P , .0001; SGRQ, 49.9 Ϯ 19.7 vs 36.6 Ϯ 20.0, P , .0001; BODE index, 3.35 Ϯ 2.04 vs 3.05 Ϯ 2.11, P 5 .033) ( Fig 1 ) . Upper-respiratory tract symptoms were greater in the CB 1 group (eg, nasal congestion, rhinorrhea) (69.3% vs 53.4%, P , .0001) as were allergic ocular symptoms (eg, itchy, watery eyes) (52.8% vs 40.2%, P , .0001). There was also a greater history of wheezing (86.5% vs 67.6%, P , .0001), nocturnal awakenings secondary to cough (45.9% vs 19.1%, P , .0001), and nocturnal awakenings secondary to dyspnea or chest tightness (39.3% vs 24.4%, P , .0001) in the CB 1 group.
In the entire cohort, current smoking was not associated with respiratory symptoms or SGRQ scores in multivariate analysis. Subjects who reported the use of supplemental oxygen had higher MMRC scores (2.94 Ϯ 1.02 vs 1.90 Ϯ 1.43, P , .0001) and more nasal symptoms (62% vs 56%, P 5 .044) than those who did not use oxygen but not other symptoms. When the presence of CB was factored into multivariate analysis, oxygen use did not have a statistically signifi cant impact on any respiratory symptoms. The use of oxygen was associated with higher SGRQ scores (49.1 Ϯ 17.1 vs 35.9 Ϯ 21.3, P , .0001), which was percentage of whites (86% vs 80%, P 5 .034) and men (57% vs 50%, P 5 .027). The CB 1 group had a greater pack-year smoking history (57 Ϯ 30 pack-years vs 52 Ϯ 25 pack-years, P 5 .006) and had more current smokers (48% vs 27%, P , .0001). There was no difference in lung function, 6-min walk distance, height, or BMI between the two groups. The OR for CB from current smoking was 2.56 (95% CI, 1.93-3.39). Comparing current smokers with ex-smokers within the Radiographic measurements are summarized in Table 2 . Percent gas trapping (CB 1 , 42.0% Ϯ 20.0%; CB 2 , 42.8% Ϯ 20.3%; P 5 .593) and percent emphysema (CB 1 , 14.2% Ϯ 13.0%; CB 2 , 16.0% Ϯ 13.4%, P 5 .212) were similar in each group. Total lung capacity (6.30 Ϯ 1.50 L vs 5.88 Ϯ 1.40 L, P 5 .0001) and functional residual capacity (4.22 Ϯ 1.19 L vs 3.92 Ϯ 1.28 L, P 5 .002) were greater in the CB 1 group. When lung volumes were adjusted for age, height, race, and sex in multivariate analysis, the differences in total lung capacity between groups remained statistically signifi cant (point estimate, 1.08; 95% CI, 1.05-1.12). Functional residual capacity, however, only tended to be different between groups after these adjustments (point estimate, 1.07; 95% CI, 0.99-2.29). There were 242 subjects in the CB 1 group and 620 in the CB 2 group with available data on radiographic airway measurements. The CB 1 group had a higher mean WA% (63.2% Ϯ 2.9% vs 62.6% Ϯ 3.1%, P 5 .013), but there was no difference in mean AWT (1.60 Ϯ 0.21 mm vs 1.60 Ϯ 0.22 mm, P 5 .700) or 10-mm diameter airway (3.800 Ϯ 0.129 mm vs 3.798 Ϯ 0.126 mm, P 5 .816).
Discussion
In this large, cross-sectional, multicenter study, we describe with great precision the clinical phenotype an independent association on multivariate analysis. In multivariate analysis with multiple logistic regression, CB was independently associated with increased respiratory symptoms when adjusting for age, current smoking, pack-year history of smoking, sex, and race ( Table 3 ) .
The CB 1 group had a greater history of exacerbations in the previous year (1.21 Ϯ 1.62 vs 0.63 Ϯ 1.12 per patient, P 5 .027), and more patients in the CB 1 group reported a history of severe exacerbations in the previous year (26.6% vs 20.0%, P 5 .024) ( Fig 2 ) . The increased exacerbation history in the CB 1 group was statistically signifi cant in multivariate analysis controlling for age, current smoking, pack-year history of smoking, sex, and race (all exacerbations prevalence ratio, 1.60; 95% CI, 1.41-1.82; severe exacerbations prevalence ratio, 1.39; 95% CI, 1.24-1.56). Within each GOLD stage, the CB 1 group had a signifi cantly greater exacerbation history. The difference in total exacerbation history was greatest in the subgroup with GOLD stage IV disease (GOLD stage II, 0.83 Ϯ 1.24 vs 0.42 Ϯ 0.82 per patient; GOLD stage III, 1.44 Ϯ 1.81 vs 0.78 Ϯ 1.30 per patient; GOLD stage IV, 1.89 Ϯ 1.91 vs 0.93 Ϯ 1.21 per patient). Current smokers in the CB 1 group had fewer exacerbations than ex-smokers (0.9 Ϯ 1.6 vs 1.5 Ϯ 1.6 per patient, P 5 .0031). e Airway data performed in a subset of patients (CB 1 , n 5 242; CB 2 n 5 620).
health-related quality of life and dyspnea are equal to or greater than the minimal clinically important difference thresholds for COPD. 29 BODE scores were higher in the CB 1 group most likely because of the higher MMRC scores. Finally, there was a higher exacerbation history in the CB 1 group, and more subjects in the CB 1 group reported severe exacerbations that required hospitalization or urgent care visits. This difference in exacerbation history was most signifi cant in subjects with GOLD stage IV disease. Exacerbation frequency has been shown to be greater in patients with COPD and CB. 16, 17, 30 Seemungal et al 16 found that CB signifi cantly increased the odds of having frequent exacerbations in a group of 70 patients. A cross-sectional analysis of 433 patients also similarly found an increased risk of exacerbation. 17 The present study validates these prior fi ndings in a much larger cohort, making the relationship between CB and risk of exacerbation more relevant to the general COPD population. We also demonstrate that the greatest difference in exacerbation history was in the patients with the worst disease severity. Although the assessment of exacerbations lacked validation from medical records and was based on patient reporting of episodes within the year prior to enrollment, the large number of patients in this study adds strength to the conclusion that CB is associated with an increased risk of exacerbation.
Another recent large observational study found a signifi cant, but weak relationship between chronic cough and exacerbation rate. 31 In comparison, the link between CB and exacerbations found in the present study is more signifi cant. Although the cohorts had similar lung function and demographics, the aforementioned study enrolled more patients with frequent exacerbations (47% of entire cohort, compared with 39% in the present one), and the incidence of CB in their cohort is unclear. These differences in subject characteristics are most likely to be responsible for the disparity in results.
Of interest, subjects with CB were more likely to be current smokers. We analyzed the effects of current smoking and found no effect on respiratory symptoms or health-related quality of life and found a lower exacerbation history than in ex-smokers. Therefore, the differences seen in symptoms and SGRQ scores between the CB 1 and CB 2 groups cannot be attributed to current smoking alone, and the fewer exacerbations in the current smokers may have been related to better lung function. In addition, there was a trend toward greater use of oxygen in subjects without CB. Although it is established that oxygen supplementation reduces breathlessness in healthy subjects and those with COPD, 32-34 the use of oxygen in the present cohort did not affect respiratory symptoms and actually was of patients with COPD and CB. With similar lung function, we found subjects with CB to be younger, have a greater smoking history, and have a greater likelihood of current smoking history than subjects without CB. Moreover, those with CB had higher SGRQ scores, a greater degree of breathlessness, and more upper-airway symptoms. These differences in Figure 1 . Dyspnea, quality of life, and BODE index in each group. A, MMRC scores. B, SGRQ scores. C, BODE index scores. MMRC scores, SGRQ scores, and BODE index scores in the CB 1 group were signifi cantly higher than in the CB 2 group. Data are presented as median (interquartile range). * P , .0001. † P 5 .033. BODE 5 BMI, airway obstruction, dyspnea, exercise capacity; CB 5 chronic bronchitis; MMRC 5 Modifi ed Medical Research Council; SGRQ 5 St. George Respiratory Questionnaire. Prevalence ratios of CB on respiratory symptoms in multivariate analysis, adjusting for age, current smoking, pack-year history of smoking, sex, and race. See Table 1 for expansion of abbreviation.
jects with CB would have a greater proportion of expiratory fl ow limitation caused by airway disease and, therefore, less emphysema and more gas trapping. Although segmental airway WA% was greater in subjects with CB, there were no statistically significant differences in the other two measures of airway disease. This inconsistency suggests that either WA% is a better barometer of airway infl ammation than the other measures or that the detected differences are not true, thereby implying that CB may be related more to large airways disease and not to the small airways. This fi nding also implies that the phenomenon of CB occurs independently from the presence or degree of emphysema. Alternatively, it is possible that our current means of airway radiographic measurement are not sensitive enough to detect real differences in airway pathology or that radiographically quantifi able differences in morphology do not exist, despite at least qualitative differences in airway infl ammation. This issue can be clarifi ed with further analysis of our current radiographic data, advances in technology, and the development of different means of quantifying airway pathology. The higher lung volumes in the CB 1 group were also curious fi ndings. These differences could not be completely explained by the differences in age, sex, and race between the two groups. 24, 35 However, it should be realized that these values were based on radiographic measurements, and lung volumes measured by plethysmography were not available in this study. At this time, the signifi cance of this fi nding is uncertain.
Nevertheless, this large cross-sectional analysis of subjects with COPD and a broad spectrum of disease severity shows with greater precision how subjects with COPD and CB are phenotypically different from subjects with COPD without CB. They are younger, more commonly men, more likely to be current associated with higher SGRQ scores, so the lower percentage of respiratory symptoms and lower SGRQ scores in the CB 2 group is not explained by oxygen use.
Whether the differences in respiratory symptoms between the two groups represent a true relationship with CB is a matter of debate. It is likely that chronic sputum production has signifi cant physiologic effects on airfl ow, causing greater dyspnea and worse healthrelated quality of life. Indeed, we have shown that in high-risk patients with severe COPD, chronic sputum production was associated with a lower peak expiratory fl ow when measured daily for up to 2 years as well as with more breathlessness and more frequent exacerbations. 18 Alternatively, it is possible that patients who have complaints of chronic cough and sputum production are simply more likely to describe worse respiratory symptoms to health-care providers without any quantifi able difference in airway infl ammation or disease severity. We also did not collect information on use of intranasal steroids or leukotriene antagonists, so it is possible that the CB 1 group described more upper-respiratory symptoms as a result of underuse of these medications. Finally, no adjustment was made for multiple comparisons, thereby raising the possibility that by chance alone a few comparisons were spuriously statistically significant. However, the differences in symptoms between the two study groups are large and highly statistically signifi cant ( P values often , .0001), and their presence in this large COPD cohort suggests that the differences are indeed real. Furthermore, the greater symptoms coupled with more exacerbations in subjects with CB underscore their clinical signifi cance.
Interestingly, the degree of emphysema and gas trapping were similar in each group, which was not consistent with the study hypothesis. We expected that for a given degree of airfl ow obstruction, sub- Figure 2 . Exacerbation rate in each group. A, Total exacerbation rate. B, History of severe exacerbations. Both total exacerbation rate (data are presented as mean Ϯ SE) and history of severe exacerbations were signifi cantly greater in the CB 1 group than in the CB 2 group. * P , .0001. † P 5 .0238. pt 5 patient. See Figure 1 legend for expansion of other abbreviation.
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The sponsor had no role in the design of the study, the collection and analysis of the data, or in the preparation of the manuscript. smokers, and more symptomatic and have more frequent comorbidities. Eliciting a history of CB can identify a group with worse lower-and upper-airway symptoms, greater risk of exacerbation, and worse prognosis. The clinician also should maintain a heightened suspicion for diabetes, coronary heart disease, osteoporosis, and sleep apnea in this patient population. This group may need more directed therapy targeting chronic mucus production and smoking cessation not only to improve symptoms but also to reduce risk, improve quality of life, and improve outcomes.
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